Among 25 people with Graves' disease, batoclimab injections led to a sharp drop in the abnormal antibodies driving the disease, and more than half were able to stop taking their thyroid medication by 12 weeks.
Claim Context
In 25 patients with Graves' disease, batoclimab treatment was associated with a mean reduction of 6.8 IU/L in thyrotropin receptor autoantibodies (TRAb) by week 1, with 56% of patients discontinuing anti-thyroid drugs by week 12.
“marked reductions from baseline in ... TRAb levels (mean [SD] change, -6.8 [5.0] IU/L) ... including 14/25 (56%) who were off ATD.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether batoclimab consistently reduces TRAb levels and enables ATD discontinuation across multiple randomized trials in Graves' disease, with standardized assays and outcome definitions.
A systematic review and meta-analysis of all randomized, double-blind, placebo-controlled trials of batoclimab in Graves' disease, including at least 500 participants, with primary outcomes of TRAb reduction ≥50% at 12 weeks and ATD discontinuation at 24 weeks, using standardized TRAb assays.
Whether batoclimab causes a greater reduction in TRAb and higher rate of ATD discontinuation compared to placebo in Graves' disease.
A double-blind, placebo-controlled, multicenter trial of 150 adults with Graves' disease and TRAb >3 IU/L, randomized 1:1 to batoclimab (680 mg then 340 mg weekly) or placebo for 24 weeks, with primary endpoints being TRAb reduction ≥50% at week 12 and ATD discontinuation at week 24 without recurrence.
Whether TRAb reduction and ATD discontinuation after batoclimab are sustained over 1–2 years in routine clinical practice.
A prospective cohort study of 300 Graves' disease patients treated with batoclimab in clinical practice, measuring TRAb levels and ATD status at baseline, 6, 12, 18, and 24 months, adjusting for baseline TRAb, age, and disease duration.
Whether baseline TRAb levels predict likelihood of ATD discontinuation after batoclimab treatment.
A case-control study comparing 50 patients who discontinued ATD after batoclimab to 50 matched controls who did not, assessing baseline TRAb titer, thyroid volume, and duration of disease as predictors.
The proportion of patients currently off ATD among those receiving batoclimab in clinical practice.
A cross-sectional survey of 500 patients with Graves' disease currently on batoclimab, measuring current ATD status and TRAb levels at a single time point.